Abstracts tagged "patient-reported outcome measures"

Abstract Number: 184 • 2013 ACR/ARHP Annual Meeting
Are Physician Gender, Age and Clinical Experience Associated With Discrepancy In Global Disease Score In Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis? Data From The Nationwide Danbio Registry
Cecilie Lindstrom Egholm¹, Niels Steen Krogh², Lene Dreyer³, Torkell Ellingsen⁴, Bente Glintborg⁵, Marcin Kowalski⁶, Tove Lorenzen⁷, Ole Rintek Madsen⁸, Henrik Nordin^9,10, Claus Rasmussen¹¹ and Merete L. Hetland¹², ¹Regional Research Unit, Region Zealand, Roskilde, Denmark, ²ZiteLab ApS, Copenhagen, Denmark, ³Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ⁴Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ⁶Aalborg University Hospital, Aalborg, Denmark, ⁷Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁸Department of Rheumatology, Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, ⁹Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹⁰DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ¹¹Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹²Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: A global estimate on a 100 mm Visual Analogue Scale (VAS) assessed by patients (PATGL) and physicians (DOCGL) is commonly used to measure disease…
Abstract Number: 2334 • 2013 ACR/ARHP Annual Meeting
ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
V. Strand¹, D. van der Heijde², C. a. F. Zerbini³, C. A. Connell⁴, D. Gruben⁴, R. Riese⁴ and G. Wallenstein⁴, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy, inhibition of structural damage, and safety of tofacitinib…
Abstract Number: 2346 • 2013 ACR/ARHP Annual Meeting
Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
Vibeke Strand¹, Keith S. Kanik², Carol Connell², Bethanie Wilkinson², David Gruben² and Gene Wallenstein², ¹Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Participation, in particular work productivity, is increasingly recognized as…
Abstract Number: 2350 • 2013 ACR/ARHP Annual Meeting
Effects Of VX-509, An Investigational Oral Selective Janus Kinase 3 (JAK3) Inhibitor, On Patient-Reported Outcomes In a Phase 2A Study Of Patients With Active Rheumatoid Arthritis
Vibeke Strand¹, Ellison Suthoff², Roy Fleischmann³, Montserrat Vera-Llonch⁴, John Jiang², Yanqiong Zhang² and Nils Kinnman⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Vertex Pharmaceuticals Incorporated, Cambridge, MA, ³Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Vertex Pharamceuticals Incorporated, Cambridge, MA, ⁵Vertex Pharmaceuticals Incorporated, Eysins, Switzerland
Background/Purpose: VX-509 is an oral JAK3 inhibitor being evaluated as a treatment for RA. Safety and efficacy results from a phase 2a, 12-week, randomized…
Abstract Number: 2329 • 2013 ACR/ARHP Annual Meeting
Improvements In Physical Function Correlate With Improvements In Health Related Quality Of Life: Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib: Results From 3 Randomized Phase 3 Trials
V. Strand¹, R. E. Alten², C. I. Nduaka³, R. Riese³, D. Gruben³, S. H. Zwillich³, J. Andrews³ and G. Wallenstein³, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Internal Medicine II, Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). RA affects all domains of health-related quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].